In line with this, a window of opportunity trial including pre-menopausal women with early BC, RANK pathway inhibition using denosumab resulted in a significant increase in TILs (NCT01864798), however, had less effect on tumour proliferation. Here, TNFRSF11A is linked to breast cancer.